Donnerstag,
16.07.2020 12:46
von
PR Newswire
| Aufrufe: 243
Johnson & Johnson Reports 2020 Second-Quarter Results:
In der Downing Street in London residieren die englischen Premierminister.
pixabay.com
PR Newswire
NEW BRUNSWICK, N.J., July 16, 2020
NEW BRUNSWICK, N.J., July 16, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. "Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment," said Alex Gorsky, Chairman and Chief Executive Officer. "Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives." Mr. Gorsky continued, "We are bringing together our best minds, our global footprint and our sophisticated supply chain technology to deliver on our commitment to provide the vaccine on a not-for-profit basis for emergency pandemic use, globally. We know the need is urgent, and every day we commit to doing our part to find a solution for the global good."
OVERALL FINANCIAL RESULTS:
| | | | SECOND QUARTER | | |||||||||||||||
| ($ in Millions, except EPS) | 2020 | 2019 | % Change ARIVA.DE Börsen-GeflüsterWerbung Weiter abwärts?
 Vontobel
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: VM1SQU,VU4F6Z,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Kurse
| ||||||||||||||||
| Reported Sales | $ 18,336 | $ 20,562 | (10.8)% | ||||||||||||||||
| Net Earnings | 3,626 | 5,607 | (35.3)% | ||||||||||||||||
| EPS (diluted) | $ 1.36 | $ 2.08 | (34.6)% | ||||||||||||||||
| | | | | ||||||||||||||||
| Non-GAAP* | SECOND QUARTER | | |||||||||||||||||
| ($ in Millions, except EPS) | 2020 | 2019 | % Change | ||||||||||||||||
| Operational Sales1,2 | N/A | N/A | (9.0)% | ||||||||||||||||
| Adjusted Operational Sales1,3 | N/A | N/A | (8.8)% | ||||||||||||||||
| Adjusted Net Earnings1,4 | 4,446 | 6,950 | (36.0)% | ||||||||||||||||
| Adjusted EPS (diluted)1,4 | $ 1.67 | $ 2.58 | (35.3)% | ||||||||||||||||
| | |||||||||||||||||||
| 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | |||||||||||||||||||
| 2 Excludes the impact of translational currency | |||||||||||||||||||
| 3 Excludes the net impact of acquisitions and divestitures and translational currency | |||||||||||||||||||
| 4 Excludes intangible amortization expense and special items | |||||||||||||||||||
REGIONAL SALES RESULTS:
| | | | SECOND QUARTER | % Change | ||||
| Adjusted | Adjusted | Adjusted | Adjusted | Adjusted | Adjusted | Adjusted | ||
| U.S. | $ 9,539 | $ 10,403 | (8.3)% | (8.3) | - | (8.1) | ||
| International | 8,797 | 10,159 | (13.4)% | (9.6) | (3.8) | (9.4) | ||
| Worldwide | $ 18,336 | $ 20,562 | (10.8)% | (9.0) | (1.8) | (8.8) | ||
| | ||||||||
| 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | ||||||||
| 2 Excludes the impact of translational currency | ||||||||
| 3 Excludes the net impact of acquisitions and divestitures and translational currency | ||||||||
| Note: values may have been rounded | ||||||||
SEGMENT SALES RESULTS:
| | | | SECOND QUARTER | % Change | ||||
| Adjusted | Adjusted | Adjusted | Adjusted | Adjusted | Adjusted | Adjusted | ||
| Consumer Health | $ 3,296 | $ 3,544 | (7.0)% | (3.6) | (3.4) | (3.4) | ||
| Pharmaceutical Werbung Mehr Nachrichten zur Johnson & Johnson Corp. Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | ||||||||
